FDA approves EUA for new anti-COVID-19 vaccine

Share this information:

THE Food and Drug Administration (FDA approved the issuance of an Emergency Use Authorization (EUA) to a new COVID-19 vaccine.

FDA Director-General Eric Domingo said the new vaccine is named Covovax, also called Novavax in the US.

Covovax is a protein sub unit vaccine according to Domingo, wherein pure antegenic part of the virus was used as a component of the vaccine.

Just like majority of the vaccine brands, two doses are needed in administering the vaccine with a gap of between 2-3 weeks.

He said that based on results of clinical trials, Covovax recorded an 89.7-percent efficacy rate and displayed very mild adverse effects.

Covovax can be added to the list of vaccine brands being used already in the country by the last part of the year or early 2022.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Next Post

IATF approves limited face-to-face classes in all universities in areas under Alert Levels 1-3

Wed Nov 17 , 2021
THE Inter-Agency Task Force for the management of Emerging Infectious Diseases (IATF) gave its approval for the holding of limited face-to-face classes in universities located in areas under Alert Levels 1 to 3. Acting Presidential Spokesperson Cabinet Secretary Karlo Alexei Nograles said a resolution was approved by the IATF for […]
%d bloggers like this: